(Q43684447)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19132294%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

"Classical 3 + 3 design" versus "accelerated titration designs": analysis of 270 phase 1 trials investigating anti-cancer agents (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19132294%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

main subject

phase I clinical trial

0 references

author

Nicolas Penel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19132294%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Pierre Leblond

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19132294%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Nicolas Isambert

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19132294%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Charles Ferte

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19132294%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Alain Duhamel

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19132294%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Jacques Bonneterre

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19132294%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

10 January 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19132294%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19132294%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19132294%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19132294%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

552-556

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19132294%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10637-008-9213-5

19 January 2020

exact match

0 references

cites work

Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.

1 reference

12 December 2020

Therapeutic response in phase I trials of antineoplastic agents

1 reference

12 December 2020

Methodology of clinical trials with new molecular-targeted agents: where do we stand?

1 reference

12 December 2020

'No risk, no fun': challenges for the oncology phase I clinical trial time-performance

1 reference

12 December 2020

Ethics of phase 1 oncology studies: reexamining the arguments and data

1 reference

12 December 2020

Prognostic factors among cancer patients with good performance status screened for phase I trials

1 reference

12 December 2020

Responses and toxic deaths in phase I clinical trials

1 reference

12 December 2020

Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents

1 reference

12 December 2020

Perceptions of cancer patients and their physicians involved in phase I trials

1 reference

12 December 2020

Response rates, duration of response, and dose response effects in phase I studies of antineoplastics

1 reference

12 December 2020

Accelerated titration designs for phase I clinical trials in oncology

1 reference

12 December 2020

Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials

1 reference

12 December 2020

Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)

1 reference

12 December 2020